
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Stomach Cancer Treatment Market**

According to Intelli, the U.S. Stomach Cancer Treatment Market size was valued at USD 1,038.65 Million in 2024 and is projected to reach USD 2,950.32 Million by 2032, growing at a CAGR of 14.36% from 2025 to 2032.



Stomach cancer, also known as gastric cancer, is a serious and often aggressive disease that originates in the lining of the stomach. It is the fifth most common cancer worldwide and the third leading cause of cancer-related deaths, largely due to its tendency to remain undetected until advanced stages. Risk factors include chronic Helicobacter pylori infection, dietary habits (high salt and smoked foods), smoking, family history, and certain genetic syndromes. Patients may present with vague symptoms including indigestion, early satiety, unintentional weight loss, or anemia, making early detection challenging. Diagnosis relies on endoscopic examination with biopsy, supplemented by imaging (CT, PET) to assess local invasion and metastasis. Treatment for stomach cancer typically involves a multidisciplinary approach, including surgery to remove the tumor, chemotherapy, radiation therapy, targeted drug therapies, and, in some cases, immunotherapy. The choice of treatment depends on the cancer’s stage, location, and the patient’s overall health. With advancements in medical technology and personalized care, outcomes have improved, especially when the disease is caught early, highlighting the importance of regular screenings and timely intervention.

**U.S. Stomach Cancer Treatment Market Definition**

The U.S. stomach cancer treatment market represents a rapidly evolving healthcare sector. This market encompasses the array of medical interventions designed to diagnose, manage, and treat gastric cancer, including chemotherapy, targeted therapy, immunotherapy, radiation, and surgical procedures.

**U.S. Stomach Cancer Treatment Market Overview**

​The U.S. stomach cancer treatment market is experiencing robust growth, propelled by several key drivers. One of the primary drivers fueling the growth of the U.S. stomach cancer treatment market is the steadily rising incidence of gastric cancer, which has created an urgent demand for more effective and comprehensive treatment solutions. In A close-up of hands holding a tablet and a pen

Description automatically generatedresponse, significant advancements in medical research and technology have given rise to cutting-edge therapies, such as precision-targeted treatments and immunotherapies, which have markedly improved patient survival rates and quality of life. These innovations are further supported by favorable reimbursement frameworks and healthcare policy reforms that have enhanced patient access to high-cost, specialized treatments. Moreover, increasing public awareness campaigns and the implementation of widespread screening initiatives have played a crucial role in promoting early detection, enabling timely and more successful medical intervention. These factors are reshaping the landscape of stomach cancer care in the U.S., driving continuous innovation, expanding treatment accessibility, and contributing to the dynamic growth of the market.

**U.S. Stomach Cancer Treatment Market Segmentation**

**​**The U.S. stomach cancer treatment market is segmented based on various parameters, reflecting the diverse approaches to managing gastric cancer.

**U.S. Stomach Cancer Treatment Market, By Treatment Type**

* **Chemotherapy**
* **Targeted Therapy**
* **Immunotherapy**
* **Radiation Therapy**
* **Surgery**

The U.S. stomach cancer treatment market exhibited a dynamic landscape across various treatment modalities. In this segment, chemotherapy and targeted therapy are pivotal components, each contributing significantly to patient care and market dynamics. As of 2024, chemotherapy maintained a substantial presence, accounting for over 40-45% of the market share, primarily due to its established role in both early-stage and advanced treatments. The growth of targeted therapies is highlighted by the approval of groundbreaking treatments like trastuzumab deruxtecan, an antibody-drug conjugate that pairs trastuzumab with chemotherapy, providing substantial survival benefits for patients with HER2-positive gastric cancer. Immunotherapy, though currently representing a smaller portion of the market, is experiencing rapid growth, driven by the approval of novel agents like PD-1/PD-L1 inhibitors, which have shown promise in enhancing patient survival A close-up of hands holding a tablet and a pen

Description automatically generatedrates. Radiation therapy and surgery remain crucial components of treatment, especially for managing localized tumors and providing palliative care. Meanwhile, the treatment landscape is evolving, with advancements in targeted and immunotherapies driving a shift toward more personalized and effective approaches to treating stomach cancer in the U.S.

**U.S. Stomach Cancer Treatment Market, By Drug Class**

* **HER2 Antagonists**
* **PD-1/PD-L1 Inhibitors**
* **VEGFR2 Antagonists**

**​**In the U.S. stomach cancer treatment market, drug classes such as HER2 antagonists, PD-1/PD-L1 inhibitors, and VEGFR2 antagonists are pivotal in shaping the therapeutic landscape. HER2 antagonists, exemplified by trastuzumab is central to treating HER2-positive gastric cancers. PD-1/PD-L1 inhibitors, like pembrolizumab and nivolumab, have proven effective in treating advanced gastric cancer, especially in tumors with microsatellite instability-high or mismatch repair deficiency. In 2024, VEGFR2 antagonists held a significant market share due to their essential role in inhibiting blood vessel formation in tumors. VEGFR2 inhibitors, such as ramucirumab helps to prevent tumor growth by blocking angiogenesis. Collectively, these drug classes contribute to a multifaceted approach in treating stomach cancer, enhancing survival rates and offering personalized treatment options for patients.

**U.S. Stomach Cancer Treatment Market, By Route of Administration**

* **Injectable**
* **Oral**

In the U.S. stomach cancer treatment market, the route of administration significantly influences therapeutic choices and patient outcomes. Injectable treatments, encompassing chemotherapy, targeted therapies, and immunotherapies, have traditionally dominated the market due to their established efficacy and comprehensive clinical validation. Conversely, oral therapies are gaining traction, particularly for patients seeking more convenient and less invasive treatment options. These include oral A close-up of hands holding a tablet and a pen

Description automatically generatedchemotherapy agents and targeted therapies, which offer the advantage of home administration, potentially improving patient adherence and quality of life.

**U.S. Stomach Cancer Treatment Market, By End User**

* **Hospitals**
* **Clinics**
* **Ambulatory Surgical Centers**
* **Specialized Cancer Treatment Centers**

In the U.S. stomach cancer treatment market, the distribution of care across various healthcare settings, hospitals, clinics, ambulatory surgical centers (ASCs), and specialized cancer treatment centers, reflects the complexity and evolving nature of cancer care. Hospitals remain the predominant setting for stomach cancer treatment, attributed to their comprehensive infrastructure, multidisciplinary teams, and capacity for complex procedures. Specialized cancer treatment centers also play a significant role, offering advanced therapies, clinical trials, and specialized care tailored to cancer patients. Clinics and ASCs are increasingly involved in the management of stomach cancer, particularly for outpatient services, follow-up care, and certain therapeutic procedures, contributing to a more patient-centric approach and potentially reducing healthcare costs.

**Key Players**

The “U.S. stomach cancer treatment market" study report will provide valuable insight emphasizing the U.S. market. The major players in the market Bristol Myers Squibb, Amgen, Incyte, Eli Lilly, Pfizer, Merck & Co., Roche, Astellas Pharma, Novartis AG, Gilead Sciences, AbbVie, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, ImmunoGen, MacroGenics, OncoOne, Novocure, Stemline Therapeutics, CytomX Therapeutics, Leap Therapeutics among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* A close-up of hands holding a tablet and a pen

  Description automatically generatedIn 2025, the FDA approved pembrolizumab combined with trastuzumab and chemotherapy for treating HER2-positive, PD-L1-positive gastric or GEJ adenocarcinoma.
* In 2024, the FDA approved tislelizumab with chemotherapy as a first-line treatment for unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma with PD-L1 expression.
* In 2024, Astellas Pharma's zolbetuximab, which targets the CLDN18.2 protein found in certain gastric cancers, was approved by the FDA.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. stomach cancer treatment market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape U.S. stomach cancer treatment market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1 **INTRODUCTION OF** **U.S. STOMACH CANCER TREATMENT MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. STOMACH CANCER TREATMENT MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. STOMACH CANCER TREATMENT MARKET, BY TREATMENT TYPE**

5.1 Overview

A close-up of hands holding a tablet and a pen

Description automatically generated5.2 Chemotherapy

5.3 Targeted Therapy

5.4 Immunotherapy

5.5 Radiation Therapy

5.6 Surgery

**6 U.S. STOMACH CANCER TREATMENT MARKET, BY DRUG CLASS**

6.1 Overview

6.2 HER2 Antagonists

6.3 PD-1/PD-L1 Inhibitors

6.4 VEGFR2 Antagonists

**7** **U.S. STOMACH CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION**

7.1 Overview

7.2 Injectable

7.3 Oral

1. **U.S. STOMACH CANCER TREATMENT MARKET, BY END USER**
   1. Overview
   2. Hospitals
   3. Clinics
   4. Ambulatory Surgical Centers
   5. A close-up of hands holding a tablet and a pen

      Description automatically generated Specialized Cancer Treatment Centers
2. **U.S. STOMACH CANCER TREATMENT MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. Company Market Ranking
   3. Key Developments Strategies
3. **COMPANY PROFILES**

**10.1 Bristol Myers Squibb**

* + 1. Overview
    2. Financial Performance
    3. roduct Outlook
    4. Key developments
  1. **Amgen**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Incyte**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Eli Lilly**
     1. Overview
     2. Financial Performance
     3. A close-up of hands holding a tablet and a pen

        Description automatically generatedProduct Outlook
     4. Key developments
  4. **Pfizer**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Merck & Co.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Roche**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Astellas Pharma**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

* 1. **Novartis AG**
     1. Overview
     2. Financial Performance
     3. A close-up of hands holding a tablet and a pen

        Description automatically generatedProduct Outlook
     4. Key developments
  2. **Gilead Sciences**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **AbbVie**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Regeneron Pharmaceuticals Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Vertex Pharmaceuticals**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **ImmunoGen**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. A close-up of hands holding a tablet and a pen

        Description automatically generatedKey developments
  7. **MacroGenics**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  8. **OncoOne**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  9. **Novocure**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  10. **Stemline Therapeutics**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments
  11. **CytomX Therapeutics**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments
  12. A close-up of hands holding a tablet and a pen

      Description automatically generated**Leap Therapeutics**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments

1. **KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Merges and Acquisitions
   3. Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

12.1 Related Research